CA Patent

CA2443128A1 — Transdermal delivery of pergolide

Assigned to Elan Pharmaceuticals LLC · Expires 2002-10-10 · 24y expired

What this patent protects

A transdermal delivery device comprising a multi-phase matrix which includes a solid liquid-retaining member and associated therewith pergolide in liquid form, for example, a transdermal delivery device comprising a barrier layer affixed to one face of the matrix and having an ex…

USPTO Abstract

A transdermal delivery device comprising a multi-phase matrix which includes a solid liquid-retaining member and associated therewith pergolide in liquid form, for example, a transdermal delivery device comprising a barrier layer affixed to one face of the matrix and having an exposed face, the exposed face having affixed thereto a mounting layer, and the other face of the matrix having affixed thereto a removable layer, an example of the liquid-retaining member being an absorbent material, for example, a natural or synthetic fiber gauze, a non-woven medical basorbent, a natural sponge, and a synthetic sponge.

Drugs covered by this patent

Patent Metadata

Patent number
CA2443128A1
Jurisdiction
CA
Classification
—
Expires
2002-10-10
Drug substance claim
No
Drug product claim
No
Assignee
Elan Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.